General Information of Drug (ID: DMCFPX8)

Drug Name
123-Iodine-labeled MFE-23 Drug Info
Synonyms
CEA antibody program (cancer/imaging); MFE-23-albumin fusion protein; CEA antibody program (cancer/imaging), Cancer Research Technology/UCL/Novozymes Delta; Albumin-linked anti-CEA single chain antibody fragment (cancer), UCL/CRT/Novozymes; Anti-CEA scFv-albumin fusion (cancer), UCL/CRT/Novozymes; 123-Iodine-labeledMFE-23; 125-I-labeled MFE-23-his; 125-Iodine-labeled MFE-23; 99mTc-labeled MFE-23
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMCFPX8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SAR408701 DMXGE3O Non-small-cell lung cancer 2C25.Y Phase 3 [3]
Tusamitamab ravtansine DMMPSA1 Non-small-cell lung cancer 2C25 Phase 3 [4]
IDM-2101 DMABRXY Colorectal cancer 2B91.Z Phase 2 [5]
CAP1-6D DMEYIVW Pancreatic cancer 2C10 Phase 2 [6]
Pentacea DMGY5JC Small-cell lung cancer 2C25.Y Phase 2 [7]
GI-6207 DM72O6F Thyroid cancer 2D10 Phase 2 [8]
CeaVac DM6Z9BV Colorectal cancer 2B91.Z Phase 2 [9]
Labetuzumab I-131 DMNO5UE Colorectal cancer 2B91.Z Phase 2 [10]
AVX701 DMOPVIQ Colorectal cancer 2B91.Z Phase 1/2 [11]
CT84.66 DM6078F Breast cancer 2C60-2C65 Phase 1/2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carcinoembryonic antigen CEA (CD66e) TTY6DTE CEAM5_HUMAN Not Available [2]

References

1 A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res. 2009 Jul 1;15(13):4484-92.
2 Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts.. Biochem J. 2000 March 1; 346(Pt 2): 519-528.
3 ClinicalTrials.gov (NCT02187848) Evaluation of SAR408701 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
4 Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416-425.
5 Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25.
6 Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 1997 Oct 15;57(20):4570-7.
7 Antibody fragments: Hope and hype. MAbs. 2010 Jan-Feb; 2(1): 77-83.
8 Clinical pipeline report, company report or official report of GlobeImmune.
9 Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol. 1999 Sep;17(9):2889-5.
10 National Cancer Institute Drug Dictionary (drug id 692828).
11 Viral vector-based therapeutic cancer vaccines. Cancer J. 2011 Sep-Oct;17(5):359-71.
12 Technology evaluation: cT84.66, City of Hope. Curr Opin Mol Ther. 2004 Feb;6(1):90-5.